PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Naldemedine - Constipation
PAD Profile : Naldemedine - Constipation Important
Keywords :
opioid induced constipation
Brand Names Include :
Rizmoic
Important Information :
Opioid-induced constipation.
Only after other laxatives have been unsuccessful.
Traffic Light Status
Status 1 of 1.
Guidelines
The following guidelines are available for this indication.
Other Drugs
- Methylnaltrexone bromide
- Ispaghula husk
- Bisacodyl
- Glycerol
- Senna
- Lactulose
- Phosphates (Rectal)
- Co-danthrusate (Dantron/docusate sodium)
- Co-danthramer (Dantron/poloxamer 188)
- Sodium citrate (Rectal)
Other Indications
No indications returned.
Additional Documents
Type
Document
Review Date
Guidelines (Local)
01 October 2022
NICE Technology Appraisal
Committee Recommendations
Date
Committee Name
Narrative
02 December 2020
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)
The Surrey Heartlands ICS Area Prescribing Committee approves naldemedine as another treatment option for Opioid Induced Constipation (OIC) in line with NICE TA651.
Naldemedine will be given a GREEN traffic light status for this indication.
Associated BNF Codes
01. Gastro-Intestinal System
01.06.06. Peripheral opioid-receptor antagonists